Wild Biotech

Wild Biotech develops a drug discovery platform harnessing evolutionary adaptations from the animal kingdom for novel miniprotein and peptide therapeutics. Its approach utilizes Wild DB, a proprietary database of over 200 million microbial genes from global biodiversity. Machine learning identifies bioactive molecules from these sources, advancing them via synthetic biology.

Founded in 2020 by CEO Neta Raab and Scientific Advisor Dr. Ido Bachelet, Wild Biotech originated from the untapped therapeutic potential in wildlife microbiota. Both founders bring scientific expertise, driving the company's mission to translate nature's resilience into pharmaceutical solutions.

Wild Biotech targets unmet clinical needs, focusing on immune and cardiometabolic disorders. The company envisions advancing innovative small peptides and miniproteins by translating natural biological solutions into therapeutic applications. This strategy aims to deliver transformative therapies, guiding candidates toward human proof of concept.

Wild Biotech is a drug-discovery platform company developing miniprotein and peptide therapeutics that leverages large microbial sequence/structure data and proprietary discovery tools to design stable, potentially orally deliverable scaffolds for bi- and multi-specific drugs aimed at pharmaceutical partners and downstream clinical development[1][2].

High‑Level Overview

• Mission: Wild Biotech positions itself as a platform innovator in drug discovery, aiming to translate microbial sequence and structural diversity into novel miniprotein and peptide therapeutics for the pharmaceutical market[1][2].[1]
• Investment philosophy / For an investment firm: N/A — Wild Biotech is a portfolio company (not an investor).
  - Key sectors: Synthetic biology, drug discovery, metagenomics, and AI-enabled protein design are core to its work[2][3].[2][3]
• Impact on the startup ecosystem: By commercializing a platform that mines massive microbial sequence databases to produce novel therapeutic scaffolds, Wild Biotech contributes to the growing ecosystem of biotech startups using metagenomics and computational design to shorten lead discovery and enable new modalities for small, stable proteins that can broaden options for pharma partnerships[1][2][3].

Origin Story

• Founding year and location: Public sources list Wild Biotech as founded around 2019 with operations tied to biotech hubs (reported locations include Rehovot, Israel, and listings that also mention Boston in profile aggregators)[3][1].[3][1]
• Founders and background / How the idea emerged: Available profiles emphasize the company’s origin in applying synthetic biology, metagenomics and AI to drug discovery, though specific founder names and biographies are not provided in the cited summaries[2][3].[2][3]
• Early traction / pivotal moments: Wild Biotech has accumulated a proprietary database claimed to contain hundreds of millions of microbial sequences and has attracted investor interest (including NFX listed among investors in some profiles), positioning the company as part of drug‑discovery tech market maps used by analysts[1][3].[1][3]

Core Differentiators

• Proprietary data scale: The company highlights a large microbial sequence/structure database (reported figures exceed 200 million microbial entries in aggregator profiles), which it uses as the raw material for novel scaffold discovery[3][2].[3][2]
• Miniprotein and peptide focus: Rather than traditional small molecules or large biologics, Wild Biotech emphasizes miniproteins and peptides engineered for stability and potential oral delivery, which can create unique therapeutic properties and manufacturing advantages[1][2].[1][2]
• Computational & synthetic biology stack: The firm combines metagenomics, synthetic biology and AI-enabled design to identify and optimize scaffolds — a differentiator versus groups relying on single-method discovery funnels[2][3].[2][3]
• Pharma-facing model: Wild Biotech is framed as a platform selling discovery outputs and partnering with pharmaceutical companies rather than a pure clinical-stage single-product company, which can accelerate translation through partnerships[1][3].[1][3]

Role in the Broader Tech Landscape

• Trend alignment: Wild Biotech rides the convergence of metagenomics, computational protein design, and a push toward smaller, stable biologic modalities — a broader industry trend aiming to expand the therapeutic toolbox beyond antibodies and small molecules[2][1].[2][1]
• Why timing matters: Advances in sequencing, machine learning for structure/function prediction, and synthetic biology-enabled synthesis and screening make microbial‑derived miniprotein discovery more feasible and commercially attractive now than a few years ago[3][2].[3][2]
• Market forces in its favor: Pharmaceutical partners are actively sourcing novel modalities and platforms to replenish pipelines, and investors/analysts are mapping drug‑discovery tech companies, creating demand for platform outputs and collaboration deals[1][3].[1][3]
• Ecosystem influence: By commercializing large-scale metagenomic databases for therapeutic design, Wild Biotech contributes to an ecosystem that validates data-driven discovery approaches and may accelerate wider adoption of miniprotein therapeutics as an alternative modality[2][3].[2][3]

Quick Take & Future Outlook

• Near-term expectations: Continued development of scaffold libraries, preclinical leads, and partnership deals with pharma would be the logical next steps for a platform like Wild Biotech; public profiles indicate the company is in the platform/discovery stage rather than late clinical stages[1][3].[1][3]
• Trends that will shape their journey: Improvements in predictive models for structure and function, advances in oral delivery technologies for peptides, and pharma appetite for novel modalities will determine how quickly platform outputs convert to partnered programs or internal pipelines[2][1].[2][1]
• How influence may evolve: If Wild Biotech translates its database and computational approach into reproducible leads and deal flow, it could become a notable supplier of miniprotein scaffolds to larger biopharma, strengthening the case for metagenomics-driven therapeutic discovery[3][1].[3][1]

Notes and limitations: Public profiles (CB Insights, aggregator sites) provide concise summaries of Wild Biotech’s platform, technology focus, and location but do not publish detailed founder biographies, full funding history, or a public pipeline; the above synthesis is based on the cited company profiles and platform summaries[1][2][3].[1][2][3]